[1] 虞珊珊,张业婷,王元鹏,等.慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨.实用肝脏病杂志,2024,27(3):329-332. [2] Wang L, Xu W, Li X, et al. Long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure: a retrospective study. BMC Gastroenterol, 2022, 22(1):162. [3] 李小英.2型糖尿病的肝源机制.中华糖尿病杂志,2023,15(2):97-99. [4] Xie J, Lin X, Fan X, et al. Global burden and trends of primary liver cancer attributable to comorbid type 2 diabetes mellitus among people living with hepatitis b: an observational trend study from 1990 to 2019. J Epidemiol Glob Health, 2024, 14(2):398-410. [5] Liu XY, Zhou Y. Influence of hepatitis B virus on the prevalence of diabetes complications in patients with type 2 diabetes. J Diabetes Investig, 2023, 14(3):429-434. [6] Yang C, Wan M, Lu Y, et al. Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection: systematic review and a meta-analysis of cohort studies. Eur J Cancer Prev, 2022, 31(2):107-116. [7] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):9-32. [8] Reddy OV, Warad VG. A prospective study to identify the prevalence of impaired glucose tolerance in patients with liver cirrhosis using oral glucose tolerance test. Cureus, 2023, 15(4):e38269. [9] Tahapary DL, Pratisthita LB, Fitri NA, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and tryglyceride/glucose index. Diabetes Metab Syndr, 2022, 16(8):102581. [10] American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care, 2021, 44(S1):S15-S33. [11] Cai T, Yue T, Xu M,et al. Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study. J Med Virol, 2023, 95(3):e28635. [12] Wang H, Zhang J. The glucose metabolic reprogramming in hepatitis B virus infection and hepatitis B virus associated diseases. J Gastroenterol Hepatol, 2023, 38(11):1886-1891. [13] García-Compeán D, Orsi E, Kumar R, et al. Clinical implications of diabetes in chronic liver disease: diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol, 2022, 28(8):775-793. [14] Zhao Y, Li D, Shi H, et al. Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian randomization study in Europeans and East Asians. Front Endocrinol (Lausanne), 2024, 15:1338465. [15] 中国医药生物技术协会慢病管理分会.肝硬化合并糖尿病患者血糖管理专家共识.实用肝脏病杂志,2022,25(5):S1-S5. [16] Coman LI, Coman OA,Bădărău IA, et al. Association between liver cirrhosis and diabetes mellitus: a review on hepatic outcomes. J Clin Med, 2021, 10(2):262. [17] Maji T, Mahto M, Kumar S, et al. Hepatogenous diabetes as compared to type-2 diabetes mellitus and non-diabetes in patients with liver cirrhosis: magnitude, characteristics, and implications. J Clin Exp Hepatol, 2024, 14(5):101411. [18] 吕呈,付文丽,谷野,等. 社区2型糖尿病人群中合并进展期慢性肝病患者的特征分析(CDL-SY):一项基于沈阳市和平区社区人群的横断面研究.中华肝脏病杂志,2022,30(11):1194-1200. [19] Abeysekera KWM, Valenti L, Younossi Z,et al. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol, 2024, 9(1):83-91. [20] Blomdahl J, Nasr P, Ekstedt M, et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism, 2021, 115:154439. [21] Whitfield JB, Schwantes-An TH, Darlay R, et al. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol, 2022, 76(2):275-282. [22] Yadav M, Verma S, Tiwari P, et al. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives. Life Sci, 2024, 15: 353:122934. [23] 田彩云,胡晗,张国远,等.肝源性糖尿病的诊断研究进展.中国全科医学,2021,24(09):1158-1164. |